Tags

Type your tag names separated by a space and hit enter

Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease.
Nutr Metab Cardiovasc Dis. 2005 Feb; 15(1):36-41.NM

Abstract

BACKGROUND AND AIM

There are only little data about the effects of lipid-lowering drugs (LLDs) on the metabolism of essential n-6 and n-3 fatty acids in patients with established coronary heart disease (CHD).

METHODS AND RESULTS

Male patients with CHD and high cholesterol levels (>6.2 mmol/L) were randomized (double-blind protocol) to receive either simvastatin 20mg (S) or fenofibrate 200mg daily (F) for 3 months. Dietary habits and plasma fatty acids were not different in the two groups at baseline. After treatment, there were significant changes in both the groups for the main n-6 fatty acids, with an increase in arachidonate (from 6.5+/-1.7% of total fatty acids to 7.5+/-2.1, p<0.001 in S and from 6.2+/-1.4 to 6.8+/-1.4, p<0.005 in F) and a decrease in linoleate (from 26.9+/-3.9 to 24.2+/-3.6, p<0.001, and from 27.8+/-3.4 to 26.1+/-4.2, p<0.05, in S and F, respectively). In addition, there was a decrease in two major n-3 fatty acids (alpha-linolenate and docosahexanoate, both p<0.05), but only in F.

CONCLUSIONS

For the first time in a double-blind randomized study in CHD patients, we report that LLDs significantly alter the metabolism of essential fatty acids that are critically important for the pathogenesis and prevention of CHD. Further studies are urgently needed to examine the effects of higher dosages of statins (as currently proposed to reduce more cholesterol) on these essential fatty acids in the clinical setting and the crucial questions of whether specific dietary intervention (combining low intake of n-6 fatty acids and high intake of n-3 fatty acids) may improve the effectiveness of these drugs.

Authors+Show Affiliations

Laboratoire Nutrition, Vieillissement et Maladies Cardiovasculaires (NVMCV), UFR de Médecine, Université Joseph Fourier, Grenoble, France. michel.delorgeril@ujf-grenoble.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15871849

Citation

de Lorgeril, Michel, et al. "Lipid-lowering Drugs and Essential Omega-6 and Omega-3 Fatty Acids in Patients With Coronary Heart Disease." Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 15, no. 1, 2005, pp. 36-41.
de Lorgeril M, Salen P, Guiraud A, et al. Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease. Nutr Metab Cardiovasc Dis. 2005;15(1):36-41.
de Lorgeril, M., Salen, P., Guiraud, A., Zeghichi, S., Boucher, F., & de Leiris, J. (2005). Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 15(1), 36-41.
de Lorgeril M, et al. Lipid-lowering Drugs and Essential Omega-6 and Omega-3 Fatty Acids in Patients With Coronary Heart Disease. Nutr Metab Cardiovasc Dis. 2005;15(1):36-41. PubMed PMID: 15871849.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease. AU - de Lorgeril,Michel, AU - Salen,Patricia, AU - Guiraud,Annabelle, AU - Zeghichi,Sabrina, AU - Boucher,François, AU - de Leiris,Joël, PY - 2004/05/12/received PY - 2004/06/25/revised PY - 2004/09/10/accepted PY - 2005/5/6/pubmed PY - 2005/11/5/medline PY - 2005/5/6/entrez SP - 36 EP - 41 JF - Nutrition, metabolism, and cardiovascular diseases : NMCD JO - Nutr Metab Cardiovasc Dis VL - 15 IS - 1 N2 - BACKGROUND AND AIM: There are only little data about the effects of lipid-lowering drugs (LLDs) on the metabolism of essential n-6 and n-3 fatty acids in patients with established coronary heart disease (CHD). METHODS AND RESULTS: Male patients with CHD and high cholesterol levels (>6.2 mmol/L) were randomized (double-blind protocol) to receive either simvastatin 20mg (S) or fenofibrate 200mg daily (F) for 3 months. Dietary habits and plasma fatty acids were not different in the two groups at baseline. After treatment, there were significant changes in both the groups for the main n-6 fatty acids, with an increase in arachidonate (from 6.5+/-1.7% of total fatty acids to 7.5+/-2.1, p<0.001 in S and from 6.2+/-1.4 to 6.8+/-1.4, p<0.005 in F) and a decrease in linoleate (from 26.9+/-3.9 to 24.2+/-3.6, p<0.001, and from 27.8+/-3.4 to 26.1+/-4.2, p<0.05, in S and F, respectively). In addition, there was a decrease in two major n-3 fatty acids (alpha-linolenate and docosahexanoate, both p<0.05), but only in F. CONCLUSIONS: For the first time in a double-blind randomized study in CHD patients, we report that LLDs significantly alter the metabolism of essential fatty acids that are critically important for the pathogenesis and prevention of CHD. Further studies are urgently needed to examine the effects of higher dosages of statins (as currently proposed to reduce more cholesterol) on these essential fatty acids in the clinical setting and the crucial questions of whether specific dietary intervention (combining low intake of n-6 fatty acids and high intake of n-3 fatty acids) may improve the effectiveness of these drugs. SN - 0939-4753 UR - https://www.unboundmedicine.com/medline/citation/15871849/Lipid_lowering_drugs_and_essential_omega_6_and_omega_3_fatty_acids_in_patients_with_coronary_heart_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0939-4753(04)00007-9 DB - PRIME DP - Unbound Medicine ER -